Enliven Therapeutics, Inc. (ELVN) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 2.98B USD. 52-week range 14.79 to 62.32 USD. Data as of 2026-10-09.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the ...